TET-activating strategies represent an exciting new avenue for cancer management, find out more in this editorial from Epigenomics.
Browsing: tumor suppressor
Researchers have uncovered a novel method of overriding the growth promoting effects of PTEN deletion and the answer is to inhibit another tumor suppressor gene.
A commentry of brain tumors associated with Li-Fraumeni syndrome, followed by a case report of the development of a rare gliosarcoma in a Li-Fraumeni patient
Researchers have demonstrated that acute myeloid leukemia patients who carry TP53 mutations respond better to a milder form of chemotherapy.
The authors review evidence on the antitumoral activity of IVIg. Fragmentary and nonconclusive, available evidences are just suggestive of the potential of IVIg in antitumoral therapy, but encourage for the generation of additional evidences through well-designed clinical trials, and for additional studies to address the molecular effects of IVIg as a means to avoid the extrapolation of data gathered from animal models.
Researchers have discovered that the mutation and inactivation of a normally protective enzyme may facilitate the metastatic spread of medulloblastoma.
Researchers have uncovered a potential new therapeutic target for lung adenocarcinomas through their work inhibiting the oncogenic protein BMI1.
Researchers have identified a gene variant that may be linked to increased risk of commonly diagnosed cancers among African–Americans.
Nit1, a conserved gene previously thought to act as a tumor suppressor, has now been shown to promote lung cancer growth in a new study.
University of Michigan Comprehensive Cancer Center study reports that AGO2 may enhance the cancer-causing ability of KRAS and suggests that the AGO2–KRAS interaction could prove to be an effective therapeutic target.